BioSpace News Archive

MedAvail Holdings, Inc. today announced that the Company will announce financial results for the first quarter ended March 31, 2023, on Thursday, May 18th, after the close of the financial markets.

Orchard Therapeutics today presented new data from the company’s hematopoietic stem cell (HSC) gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Los Angeles.

EyePoint Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement for the sale of YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18mg to Alimera Sciences, Inc. (“Alimera”).

PepGen Inc. today announced that the company has received a No Objection Letter (NOL) for its Clinical Trial Application (CTA) from Health Canada for its Phase 2 CONNECT1-EDO51 study to initiate an open label, multiple ascending dose (MAD) clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) amenable to an exon 51 skipping approach.

Standard BioTools Inc. today announced the launch of NGS library preparation functionality on the X9™ High-Throughput Genomics System.

Impulse Dynamics plc announced the completion of the first implantation for the INTEGRA-D clinical trial, designed to evaluate the safety and efficacy of two proven cardiac therapies combined — CCM ® and an implantable cardioverter defibrillator (ICD) — in a single device (CCM-D).

BridGene Biosciences, Inc. announced that Wolf Wiedemeyer , Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & Combination Potential,” at the 2nd Annual Hippo Pathway Targeted Drug Development Summit on May 24 in Boston.

Oramed Pharmaceuticals Inc. announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA , on May 31, 2023.

Motus GI Holdings, Inc. announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 4,142,012 shares of its common stock and warrants to purchase up to an aggregate of 4,142,012 shares of common stock, at a purchase price of $0.845 per share and accompanying warrant in a private placement priced at-the-market under Nasdaq rules.

Xtant Medical Holdings, Inc. today announced the appointment of Lori Mitchell-Keller to the Company’s Board of Directors effective May 16, 2023.